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Abstract
Background: Primary bone cancers are among the deadliest cancer types in adolescents, with osteosarcomas
being the most prevalent form. Osteosarcomas are commonly treated with multi-drug neoadjuvant chemotherapy
and therapy success as well as patient survival is affected by the presence of tumor suppressors. In order to assess
the prognostic value of tumor-suppressive biomarkers, primary osteosarcoma tissues were analyzed prior to and
after neoadjuvant chemotherapy.
Methods: We constructed a tissue microarray from high grade osteosarcoma samples, consisting of 48 chemotherapy
naïve biopsies (BXs) and 47 tumor resections (RXs) after neoadjuvant chemotherapy. We performed immunohistochemical
stainings of P53, P16, maspin, PTEN, BMI1 and Ki67, characterized the subcellular localization and related staining
outcome with chemotherapy response and overall survival. Binary logistic regression analysis was used to analyze
chemotherapy response and Kaplan-Meier-analysis as well as the Cox proportional hazards model was applied for
analysis of patient survival.
Results: No significant associations between biomarker expression in BXs and patient survival or chemotherapy
response were detected. In univariate analysis, positive immunohistochemistry of P53 (P = 0.008) and P16 (P16;
P = 0.033) in RXs was significantly associated with poor survival prognosis. In addition, presence of P16 in RXs was
associated with poor survival in multivariate regression analysis (P = 0.003; HR = 0.067) while absence of P16 was
associated with good chemotherapy response (P = 0.004; OR = 74.076). Presence of PTEN on tumor RXs was
significantly associated with an improved survival prognosis (P = 0.022).
Conclusions: Positive immunohistochemistry (IHC) of P16 and P53 in RXs was indicative for poor overall patient
survival whereas positive IHC of PTEN was prognostic for good overall patient survival. In addition, we found that P16
might be a marker of osteosarcoma chemotherapy resistance. Therefore, our study supports the use of tumor RXs to
assess the prognostic value of biomarkers.
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Background
Osteosarcoma is the most common malignancy of bone
and among the deadliest cancers in adolescents [1, 2].
Osteosarcoma patients are commonly treated with mul-
tiagent neoadjuvant chemotherapy, combined with sur-
gery to remove the primary tumor mass and subsequent
adjuvant chemotherapy. Introduction of chemotherapy
has increased the mean 5-year survival rates of patients
with localized disease from 20 % in the early 1970s to
above 60 % at present [1, 3]. In contrast, the presence of
metastases is a strong prognostic factor for poor survival
rates of 30 % or less [4].
Specifically for osteosarcoma, a patient’s response to
neoadjuvant chemotherapy has a considerable prognos-
tic value and has therefore replaced single adjuvant
chemotherapy [5, 6]. To date, necrosis of tumor resec-
tions (RXs) above 90 %, although only a crude read out,
is still used in clinical practice due to its prognostic
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power for patient survival [4, 7]. Current protocols of
neoadjuvant chemotherapy for routine use in osteosar-
coma are based on combinations of highly cytotoxic
drugs such as cisplatin, methotrexate and doxorubicin
[8]. Although potent, these drugs are not specific enough
and tumor resistance, subsequent disease progression as
well as patient death are therefore frequently observed.
Consequently, numerous immunohistochemical studies
have tried to identify osteosarcoma-biomarkers. For in-
stance, VEGF [9-11], ezrin [12-14], P53 [15], P16 [16],
CD44 [17], CXCL12 [18] were evaluated as prognostic fac-
tors for survival, whereas immunohistochemical stainings
of nuclear P16 [19], CRIP1 [20] and COX-2 [21] were in-
vestigated as predictors of chemotherapy response.
However, the above mentioned studies only evaluated
chemotherapy naïve biopsies (BXs) of osteosarcomas.
Despite the larger amounts of available tissue compared
to needle biopsied tissue, fewer studies analyzed RXs
because it is thought that no valid prediction about pa-
tient survival can be made. Nevertheless, analysis of
marker expression in remaining viable tumor tissue after
chemotherapy can be investigated similar to assessing
the degree of response to chemotherapy [22], and may
yield important information about patient prognosis and
the impact of chemotherapy in non-responders. Simi-
larly, only a few studies analyzed RXs of osteosarcomas
in order to study expression changes of biomarkers prior
to and after chemotherapy yet in these studies significant
correlations were found between clinicopathological pa-
rameters and expression changes of biomarkers such as
VEGF [23], MMP-2 [24], ezrin [25] and alkaline phos-
phatase [26].
Tumor suppressors are thought to have a major impact
on the response to chemotherapy [27-30] and hence,
patient survival. In this study, we therefore analyzed
immunohistochemical stainings in BXs and RXs of four
established tumor suppressors (P53, P16, PTEN and mas-
pin) in viable patient-derived tissue before and after
neoadjuvant chemotherapy in order to better understand
their changes during chemotherapy, and to find out if this
change is related to chemotherapy response or survival.
Wild-type P53 is a major player in the DNA damage re-
sponse and initiates cell apoptosis once the extent of
DNA damage is beyond repair [31]. Intriguingly, wild-
type P53 also has the ability to protect tumors during
chemotherapy [27], highlighting the need for a better
characterization of P53 as a marker during chemotherapy.
P53 is well known to be mutated in high grade osteosar-
comas [15, 32] and mutant P53 is often detected by im-
munohistochemistry (IHC) due to its increased half-life
[33], highlighting its potential as a valuable marker for
osteosarcoma patient prognosis.
P16 is considered another major tumor suppressor
and acts through blocking of cyclin dependent kinase 4
signaling and consequently, cell cycle progression [34].
P16 as a biomarker is less well characterized than P53 in
osteosarcoma. Nevertheless, the use of osteosarcoma
BXs identified P16 as a sensitive prognostic factor [35]
and to be predictive for good chemotherapy response
[19]. In contrast to what is inferred from biopsied sam-
ples, changes in P16 might protect the tumor cells dur-
ing chemotherapy by decreasing their proliferation rate
[28]. Therefore, it is of importance to not only study the
presence of individual tumor suppressors but to also in-
vestigate their impact on tumor proliferation (e.g., moni-
toring of Ki67 [36]). Tumor proliferation measured by
Ki67 indices is believed to have strong prognostic value
in multiple types of cancer [37-39]. Proliferation is the
result of an excess of growth promoting signals such as
growth-factor signaling pathways or the inhibition of cell
cycle regulators. Thus, proliferation can be altered at vari-
ous levels, for instance through upregulation of BMI1,
causing a deactivation of P16 and hence, an increase in
proliferation [40]. At the same time, BMI1 was found
to be overexpressed in more than half of chemotherapy
naïve osteosarcoma specimens [41]. To date, no sig-
nificant correlation between clinicopathological pa-
rameters and BMI1 expression in osteosarcomas was
discovered.
Two additional tumor suppressors, maspin and PTEN,
have hardly been studied in the context of osteosarcoma
so far. Similar to P16 [34], PTEN controls cell prolifera-
tion by regulating cyclin D levels and inhibiting PI3K-
Akt signalling [42]. Thus, presence of PTEN in tumor
specimens is considered as being prognostic for good
patient survival [43, 44]. The precise mechanism of mas-
pin, on the other hand, is still under debate. On the one
hand, studies showed a reduced metastatic potential of
breast cancer cells [45] or augmented cancer cell death
by chemotherapeutic drugs through induction of maspin
[29] and, on the other hand, studies demonstrated in-
creased expression of maspin to be an indicator of poor
survival [46] or poor chemotherapy response [47]. These
controversial results suggest that expression changes of
maspin are rather secondary effects caused by similar
changes to adjacent and more relevant genes, further
supported by a recent study [48].
Drugs used in current chemotherapeutic protocols to
treat osteosarcomas generally induce tumor cell death, yet
some tumors adapt in order to avoid death. In order to
identify patients at risk, we studied the before mentioned
biomarkers in primary osteosarcoma tissues before and
after chemotherapy. Using immunohistochemistry (IHC),
we evaluated associations between the presented bio-
markers and clinical parameters such as overall survival,
response to chemotherapy, metastasis or proliferation of
the primary tumor in order to assess the clinical value of
the studied biomarkers.
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Methods
Patient samples
This retrospective study was conducted with tumor tis-
sue specimens from a total of 61 patients who were op-
erated between December 1987 and October 2005. The
specimens were retrieved from the archive of the Insti-
tute of Surgical Pathology of the University Hospital,
Zurich, Switzerland. All tissue samples were graded as
high grade osteosarcomas according to the current
histopathological classification by the World Health
Organization [49]. Follow-up was started at first diagno-
sis of the osteosarcoma and ended at death or with the
last clinical record in our hospital database giving a
range of 7–210 months with a median follow-up of 85
(BX) and 90 (RX) months. All patients used for survival
analysis had a complete clinical record and a follow-up
of at least 50 months. Patients receiving complete neo-
adjuvant chemotherapy according to the formerly used
COSS protocols, namely COSS-86, COSS-91 and COSS-
96 [50, 51] were retrospectively selected and the corre-
sponding clinical records were reviewed and updated.
Tumor response was evaluated based on the grading of
tumor necrosis according to the guidelines by Salzer-
Kuntschik et al. [22]. Patients were termed “responders”
if tumor necrosis, based on histopathological analysis,
was greater than 90 % after neoadjuvant chemotherapy
and “non-responders” if less than 90 % of the tumor was
necrotic. Ultimately, panels of 47 chemotherapy naïve
biopsies (herein termed BXs), 44 neoadjuvant chemo-
therapy treated tumor samples (i.e., resections, herein
termed RXs) and 11 lung metastasis-derived tissues
were analyzed. In a maximum of 31 cases, a matched
chemotherapy-naïve BX and neoadjuvant chemotherapy
treated RX of the same patient were obtained and used
for the analysis of changes of IHC in BXs and RXs de-
rived from the same patient.
Tissue microarray
In this study a tissue microarray (TMA) containing
paraffin-embedded primary tumor material (both BXs and
RXs as well as lung metastases, see ref [52]) was used to as-
sess marker expression. Based on hematoxylin and eosin
stained sections of the tumor, viable tumor cell containing
areas were selected for the construction of the TMA. All
BX-derived available tissue cores with sufficient numbers
of tumor cells were evaluated. For RX derived material,
only tissue cores derived from “non-responders” (defined
as Salzer-Kuntschik grade 4–6) and “responders” (Salzer-
Kuntschik grade 2 and 3) were considered for analysis, due
to a lack of viable tissue in grade 1 “complete responders”.
Immunohistochemistry and TMA analysis
Immunohistochemistry (IHC) was carried out on 4 μm
sections of the TMA. Sections were transferred to an
adhesive-coated slide system (Instrumedics, Hackensack,
NJ, USA), deparaffinized, and processed with an auto-
mated Ventana Benchmark staining system (Ventana
Medical Systems Tucson, Arizona, USA). Heat-mediated
antigen retrieval was performed with cell conditioner 1
for at least 30 min. Individual sections were probed
with the following antibodies: mouse monoclonal anti-
P16ink4a (clone 16P04, dilution 1:600; LabVision/Neo-
markers, USA), mouse monoclonal anti-P53 (clone
DO-7, dilution 1:80; Dako, DNK), mouse monoclonal
anti-PTEN (dilution 1:200; clone 28H6; Leica Biosys-
tems/Novocastra, GER), mouse monoclonal anti-maspin
(clone G167-70, dilution 1:200, BD Pharmingen, USA),
mouse monoclonal anti-BMI1 (clone F6, dilution 1:50;
Millipore/Upstate, USA) and mouse monoclonal anti-Ki67
(clone MIB-1, dilution 1:20; Dako, DNK). Visualization of
the antibody binding was done by applying the iVIEW
DAB Kit (Ventana Medical Systems Tucson, Arizona,
USA). Slides were counterstained with hematoxylin. A
pathologist (CP) and an instructed scientist (BR) independ-
ently analyzed the tissue cores in a blinded fashion, where
special attention was given to the subcellular (nuclear or
cytoplasmic) localization of the analyzed marker. A con-
sensus grading was formed in case of differences between
individual samples. At least two cores per patient sample
were analyzed to compensate for tissue heterogeneity. Tis-
sue cores were graded as “negative” (grade 0) if less than
10 % of the tumor cells were stained, as “positive” (grade 1)
if between 10 and 50 % of the tumor cells were immuno-
stained with intermediate or high intensity and as “strongly
positive” (grade 2) if more than 50 % of the tumor cells
were stained with high intensity. In addition, changes of
biomarkers following chemotherapy were investigated
by comparing the immunohistochemical grades of BXs
and RXs of the same patient. These changes were clas-
sified as “increase”, “no change” or “decrease” of the re-
spective biomarker.
Statistical analysis
Kaplan-Meier curves were used to calculate overall pa-
tient survival, which was defined as the time from diag-
nosis until death or until last follow-up. Log-rank tests
were used to assess the statistical difference between
groups. Multivariate Cox regression models were used
to calculate hazard ratios (HRs) and 95 % confidence in-
tervals (CIs). The clinicopathologic factors patient age,
gender, location of primary tumor occurrence and histo-
logical subtype of osteosarcoma were included as covariates
next to expression of individual biomarkers. Multivariate
binary logistic regression models were used to estimate
Odds ratios (ORs) as well as 95 % CIs. To determine associ-
ations between biomarker expression and other parameters
(i.e., proliferation (Ki67 immunostaining); presence of me-
tastasis) Fisher’s exact tests were applied. All statistical tests
Robl et al. BMC Cancer  (2015) 15:379 Page 3 of 12
were 2-sided where P < 0.05 was regarded as statistically
significant. PASW Statistics 18.0 (IBM Corp., USA) was
used for statistical evaluation.
Ethics statement
The design of this retrospective study was assessed and
approved by the local ethics committee of the Univer-
sity Hospital Zurich (approval reference number StV
41–2005).
Results
Patient cohort characteristics
As depicted in Table 1, the two patient cohorts used for
analyses of BXs or RXs had similar clinicopathological
characteristics. In both cohorts, the majority of the pa-
tients were male (BX: 60 %, RX: 64 %) and the overall
mean age was 18.4 years and 18.0 years in the BX cohort
and RX cohort, respectively. Most osteosarcomas were
seen in patients aged 10–24 years (BX: 65 %, RX: 66 %).
The distribution of histological subtypes such as the pre-
dominant osteoblastic type (BX: 71 %, RX: 70 %) or the
main sites of primary tumor occurrence such as the tibia/
fibula/ calcaneus (BX: 40 %, RX: 32 %) or the femur (BX:
38, RX: 43 %) were similar in both patient cohorts. A total
of 65 % (BX) and 68 % (RX) of patients were alive at the
last follow-up resulting in similar five-year survival rates
of 65 % (BX) and 68 % (RX). Chemotherapy response
(≥90 % tumor necrosis) subsequent to neoadjuvant
chemotherapy was found in 54 % (BX) and 49 % (RX) of
the patients compared to 46 % (BX) and 51 % (RX) being
non-responders (<90 % tumor necrosis). During follow-
up, 44 % (BX) and 38 % (RX) of patients developed
metastases.
Tumor IHC
Representative examples of positive as well as negative
immunohistochemical stainings of BXs are given in
Fig. 1. The subcellular localization differed between the
analyzed markers: IHC of P53 (Fig. 1b), Maspin (Fig. 1d),
Ki67 (Fig. 1e) and BMI1 (Fig. 1f ) showed nuclear
localization in >90 % of the positively stained BXs. In
contrast, PTEN (Fig. 1c) was exclusively found in the
cytoplasm. Subcellular localization of P53, Maspin, Ki67,
BMI1 and PTEN in RXs was the same as in BXs. IHC of
P16 (Fig. 1a) showed equal numbers of “cytoplasmic
and nuclear” as well as “cytoplasmic only” (see Additional
file 1) P16-positive BXs (52 % versus 48 % of the BX sam-
ples, respectively). In P16-positive RXs, “cytoplasmic only”
expression of P16 was more frequent than “cytoplasmic
and nuclear” localization of P16 (65 % versus 35 % of the
RX samples, respectively). Furthermore, all P16-positive
osteosarcoma samples had detectable P16 in the cyto-
plasm of cancer cells, whereas no sample was found with
a “nuclear only” subcellular localization of P16.
Table 1 Clinicopathologic characteristics of high-grade
osteosarcoma patients and IHC of six biomarkers
Variables nBX %BX nRX %RX
All high grade osteosarcoma 48 100 47 100
Neoadjuvant chemotherapy 48 100 47 100
Sex
Female 19 40 17 36
Male 29 60 30 64
Patient age
<10 years 10 21 9 19
10–24 years 31 65 31 66
>24 years 7 15 7 15
Histological subtype
Osteoblastic 34 71 33 70
Chondroblastic 4 8 7 15
Fibroblastic 5 10 4 9
Telangiectatic 5 10 3 6
Location
Tibia / Fibula / Calcaneus 19 40 15 32
Femur 18 38 20 43
Humerus / Ulna 6 13 5 11
Axial 5 10 7 15
Pathologic Response
Responder 26 54 24 49
Non-Responder 22 46 23 51
Metastasis
Yes 21 44 18 38
No 27 56 29 62
P16 total (nmatchedBX-RX = 27) 44 100 39 100
P16positive 25 57 17 44
P16negative 19 43 22 56
P53 total (nmatchedBX-RX = 31) 47 100 44 100
P53positive 9 19 12 27
P53negative 38 81 32 73
PTEN total (nmatchedBX-RX = 10) 40 100 22 100
PTENpositive 25 63 7 32
PTENnegative 15 37 15 68
Maspin total (nmatchedBX-RX = 21) 39 100 33 100
Maspinpositive 26 67 10 30
Maspinnegative 13 33 23 70
Ki67 total (nmatchedBX-RX = 15) 43 100 25 100
Ki67positive 24 56 8 32
Ki67negative 19 44 17 68
BMI1 total (nmatchedBX-RX = 16) 42 100 28 100
BMI1positive 11 26 2 7
BMI1negative 31 74 26 93
BX biopsy, RX resection
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Table 1 also indicates the numbers of samples available
for each analyzed marker. In general, a larger number of
BXs (nBX: 39–47) was available for IHC compared to
specimens derived from RXs (nRX: 22–44). A positive
BX staining was most often found for maspin and
PTEN, in with approximately two thirds of the samples
were positively stained. Staining of P53 and BMI1 was
less common, with 19 % and 26 % positive staining, re-
spectively. In over half of the BXs, Ki67 (56 %) and P16
(57 %) could be detected. As depicted in Table 1, chemo-
therapy decreased the immunohistochemical grade of
P16, PTEN, maspin, Ki67 and BMI1, i.e., led to a de-
creased expression of the marker in the patient samples
after chemotherapy. This decrease was most dramatic
for BMI1 and maspin, where in relative terms, more
than half of the samples lost their marker expression. In
contrast, a relative increase of P53-positive samples was
observed after chemotherapy (BX, positive: 19 %; RX,
positive: 27 %).
Survival analysis
As depicted in Fig. 2. Kaplan-Meier survival analysis of
chemotherapy-naïve BXs of high grade osteosarcoma pa-
tients yielded no significant differences in overall sur-
vival for the various biomarkers, although for P53 a
trend was observed for worse survival in case of pres-
ence of nuclear P53 (P = 0.083; Fig. 2b). In contrast, the
analysis of patient RXs yielded significant differences in
overall survival as illustrated in Fig. 3. Positive expres-
sion of P16 (P = 0.033; Fig. 3a) and P53 expression
(P = 0.008; Fig. 3b) were found to be prognostic markers
for poor overall survival of patients. In contrast, absence
of PTEN (P = 0.022; Fig. 3c) in patient RXs was signifi-
cantly associated with worse overall survival. Expression
of maspin (Fig. 3d), Ki67 (Fig. 3e) and BMI1 (Fig. 3f ) in
RXs was not significantly associated with overall survival
prognosis. Due to the fact that P16 was present in the
“cytoplasm only” or in the “cytoplasm and nucleus” of
some samples, we sought to see if there is a difference in
survival rates between these two subgroups. However,
Kaplan-Meier survival analysis did not yield a difference
in survival probability according to the subcellular
localization of P16 (see Additional file 2).
Cox regression analysis (Table 2A) demonstrated that
no significant contribution of any biomarker was de-
tected in BXs (data not shown), but in RXs, absence of
P16 expression (P = 0.003; HR = 0.067; 95 % CI: 0.011 -
0.397) was a significant favorable prognostic factor for
overall survival. The other biomarkers were not found to
be associated with overall survival (Table 2). Similarly,
clinicopathologic parameters such as age, gender, tumor
location or tumor subtype possessed no prognostic value
for patient survival in multivariate analyses.
Chemotherapy response
Chemotherapy response of the tumor following chemo-
therapy has a strong influence on patient survival progno-
sis. Therefore we used binary logistic regression to analyze
the expression of biomarkers on BXs in connection with
gender, patient age, location of tumor and histological
subtype to determine the predictive value on tumor re-
sponse. Female gender was the only significant predictive
factor for good chemotherapy response after neoadjuvant
chemotherapy using multivariate analysis for models with
BMI1, Ki67, PTEN, P16 and P53 (data not shown). In the
multivariate model established for maspin, no such link
between female gender and good chemotherapy response
was detected.
Fig. 1 Representative images of immunohistochemistry of the six analyzed biomarkers. For each part (a–f) the same order of samples is shown: left
(positive staining), middle (negative staining), right (positive staining of a lung metastasis). a, nuclear and cytoplasmic P16 staining. b, nuclear P53. c,
cytoplasmic PTEN. d, nuclear maspin. e, nuclear Ki67. f, nuclear BMI1. Normalized magnification of all images, 40x; Hematoxylin counterstaining
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Fig. 2 Univariate Kaplan-Meier survival analysis of biomarkers in BXs. Kaplan-Meier survival curves showing survival probabilities of patients according
to their (a) P16, (b) P53, (c) PTEN, (d)x maspin, (e) Ki67 and (f) BMI1 expression status
Fig. 3 Univariate Kaplan-Meier survival analysis of biomarkers in RXs. Kaplan-Meier survival curves showing survival probabilities of patients according
to their (a) P16, (b) P53, (c) PTEN, (d) maspin, (e) Ki67 and (f) BMI1 – expression status
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In RXs, a correlation between tumor response after neo-
adjuvant chemotherapy and biomarker expression was de-
tected. Expression of P16 in RXs was the only biomarker
showing a significant correlation with poor tumor re-
sponse after chemotherapy (absence of P16 in RXs:
P = 0.004; OR = 74.076; 95 % CI:3.875-1415.946; Table 2B).
None of the other biomarkers analyzed in RXs returned a
significant correlation with tumor response.
Proliferation
In order to see if a link exists between expression of the an-
alyzed biomarkers and proliferation, we correlated expres-
sion of P53, P16, maspin, PTEN or BMI1 with Ki67 (see
Additional file 3). We found maspin expression to be posi-
tively correlating with Ki67 expression in osteosarcoma tis-
sues (PBX <0.001, PRX = 0.008; Fisher’s exact test). Similarly,
PTEN expression positively correlated with Ki67 expres-
sion (PBX = 0.018, PRX = 0.046; Fisher’s exact test). Interest-
ingly, IHC of P16 (PBX = 0.050, PRX = 0.086; Fisher’s exact
test) showed a borderline correlation whereas P53 did not
significantly correlate with Ki67 on osteosarcoma samples.
Despite the low number of BMI1 positive RXs, positive
IHC of BMI1 on BXs showed a significantly positive
correlation with the tumor proliferation marker Ki67
(PBX = 0.001, PRX = 0.505; Fisher’s exact test).
Metastasis
Compared to primary tumor material, a higher percentage
of lung metastases showed expression of the analyzed
markers (examples are shown in Fig. 1, right colums).
More than 50 % of positively stained samples were found
in 91 % (P16), 82 % (PTEN and maspin), 60 % (Ki67) and
55 % (BMI) of all available lung metastases. In contrast,
positive P53 staining was only present in 18 % of all avail-
able lung metastases.
In both BXs and RXs, no statistically significant correla-
tions between the expression of any of the investigated bio-
markers and the development of metastases during follow-
up were detected. Analyses of BXs and RXs stained for P16,
P53, PTEN (BXs), Ki67, Maspin and BMI1 all yielded
P-values > 0.35 (Fisher’s exact test) except for the analysis of
PTEN in RXs, where presence of PTEN was indicative for
suppression of metastases (P = 0.063, Fisher’s exact test).
Changes of biomarkers
We investigated if changes in the histological grading of
each marker (i.e., in BX and RX derived from the same
Table 2 Multivariate analysis of patients with osteosarcomas receiving neoadjuvant chemotherapy
A. Cox regression analysis of association between
clinicopathologic variables and overall survival
B. Binary logistic regression analysis of association between
clinicopathologic variables and tumor-response status
Variablesa P-value HR 95 % CI P-value OR 95 % CI
Age 0.973 0.126
<10 years 0.829 0.000 0.000 ∞ 0.043 0.006 0.000 0.845
10–24 years 0.922 0.876 0.063 12.227 0.084 0.012 0.000 1.814
Gender 0.122 4.390 0.674 28.596 0.609 2.189 0.109 44.045
Location 0.972 0.601
Tibia/ fibula/calcaneus 0.743 0.000 0.000 ∞ 0.999 6.119E9 0.000 ∞
Femur 0.737 0.000 0.000 ∞ 0.999 4.232E9 0.000 ∞
Humerus/ulna 0.719 0.000 0.000 ∞ 0.999 5.229E10 0.000 ∞
Histological subtype 0.902 0.935
Chondroblastic 0.986 0.139 0.000 ∞ 0.999 8.367E8 0.000 ∞
Fibroblastic 0.922 22186 0.000 ∞ 0.999 0.000 0.000 ∞
Osteoblastic 0.932 6308 0.000 ∞ 0.514 5.300 0.036 789.165
RX P16 negative (n = 39) 0.003 0.067 0.011 0.397 0.004 74.076 3.875 1415.946
RX P53 negative (n = 44) 0.315 0.515 0.141 1.879 0.159 4.786 0.541 42.368
RX PTEN negative (n = 22) 0.166 5.342 0.498 57.310 0.999 2.169E9 0.000 ∞
RX Maspin negative (n = 33) 0.409 0.482 0.085 2.725 0.192 4.384 0.477 40.278
RX Ki67 negative (n = 25) 0.069 0.157 0.021 1.157 0.999 1.934E9 0.000 ∞
RX BMI1 negative (n = 28) 0.353 3.624 0.239 54.951 1.000 0.000 0.000 ∞
In the upper section, the multivariate analysis including P16 is shown. In the lower section, statistical parameters of biomarker expression of separate multivariate
analyses (including the same clinicopathologic factors from the upper section) are shown
RX resection, HR hazard ratio, OR Odds ratio, ∞ infinity
aCoding of variables was a follows: age: 1 (<10 year), 2 (10–24 years) and 3 (>24 year). Gender: 1 (female) and 2 (male). Location: 1 (tibia/ fibula/ calcaneus),
2 (femur), 3 (humerus/ ulna) and 4 (axial sites). Histological subtype: 1 (chondroblastic) 2 (fibroblastic), 3 (osteoblastic) and 4 (telangiectatic)
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patient) had a prognostic value for patient survival.
Despite a limited number of matched patient tissues
available (n = 10–31, exact sample numbers indicated in
Table 1), we found that changes in gradings of Ki67
(P = 0.0004, log-rank test) and maspin (P = 0.029, log-
rank test) had significant prognostic value for overall
survival (Fig. 4), where a decrease in grading of both
markers was associated with better survival compared
to no change or an increase. Changes of biomarker grad-
ings were neither significantly correlating with the forma-
tion of metastasis nor with chemotherapy response (data
not shown).
Discussion
We strongly believe that, especially in case of rare cancer
entities such as osteosarcoma, all available tissue should
be analyzed in order to gain more information about the
molecular changes of the osteosarcoma during chemo-
therapy. By careful selection of the still viable resected
material, valuable information can be obtained about pa-
tient survival prognosis or chemotherapy response. Here,
we thus demonstrated prognostic roles of P53, P16 and
PTEN in osteosarcoma by analyzing osteosarcoma sam-
ples after neoadjuvant chemotherapy. The prognostic
value of P16 [53-55], P53 [15] as well as PTEN [43, 44]
found in our study confirmed data found in other can-
cers. In addition to the common perception of analyzing
chemotherapy naïve tissues in order to identify prognos-
tic markers, we also demonstrated the value of analyzing
(matching) resected tumor tissue.
To date, hardly any studies analyzing matched osteo-
sarcoma patient samples prior to and after neoadjuvant
chemotherapy exist. For the first time, we showed sig-
nificant correlations between changes of maspin as well
as Ki67 and osteosarcoma patient survival. In general,
little is known about the role of maspin in cancer pro-
gression and it is questioned if maspin is playing a role
in tumor development, in particular breast cancer, at all
[48]. We are the first to study whether a metastasis-
suppressing role of maspin exists in osteosarcoma, yet we
could not detect a significant correlation between maspin
expression in BXs or RXs and the development of metas-
tases or any other clinicopathological parameter. However,
we found that an increase in maspin expression in
matched tumor specimens (prior to and after chemother-
apy) had a worse survival prognosis compared to patients
in which maspin gradings decreased or remained un-
changed. Explanations for this finding might be either the
formation of mutants of maspin [56] or the induction of
maspin expression by chemotherapeutics [29] without a
direct impact on tumor biology [48]. In contrast, IHC of
the proliferation marker Ki67 is often discussed as a
strong prognostic factor, for instance in Ewing’s sarcomas
[57] or breast cancer samples [38]. Despite low patient
Fig. 4 Univariate Kaplan-Meier survival analysis of biomarker expression changes prior to and after neoadjuvant chemotherapy in matched tissue
samples. Kaplan-Meier survival curves showing survival probabilities of patients designated by the changes of IHC gradings of (a) P16, (b) P53, (c)
PTEN, (d) maspin, (e) Ki67 and (f) BMI1
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numbers and although IHC of Ki67 was not significantly
linked to patient survival in our and another osteosarcoma
study [58], changes of Ki67 IHC scores had prognostic
value for poor survival. Thus, one can speculate that osteo-
sarcomas with increased proliferation rates might possess a
survival advantage during cisplatin-based chemotherapy
and ultimately lead to poorer patient survival. However, as
the number of matched samples was limited, repetition of
these analyses in a larger cohort should be performed.
With respect to P16, studies so far only focussed on
the role of nuclear P16 in osteosarcoma. Positive expres-
sion of nuclear P16 was considered to be beneficial for
overall survival rates of osteosarcoma patients [16] as
well as predictive for good response after standard neo-
adjuvant chemotherapy [19]. These two studies investi-
gated the role of nuclear P16 in chemotherapy naïve
samples [16, 19] and showed that nuclear P16 suppressed
the formation of osteosarcoma and increased the chances
of success of neoadjuvant chemotherapy. Importantly, P16
in our study was predominantly present in the cytoplasm
of positively stained samples, and hence, was related to a
poor chemotherapy response and poor patient survival.
This difference may be related by different functions of
P16 in the nucleus and cytoplasm, or simply reflect the
fact that cytoplasmic P16 is not available to exert its regu-
latory function inside the nucleus. In general, these find-
ings are in line with studies describing other cancer types
which claimed cytoplasmic P16 to be an indicator for ad-
vanced tumor stages [59] and increased aggressiveness of
squamous cell carcinomas of the skin [60] or the cervix
[61]. Analysis of BXs of head and neck tumors signifi-
cantly linked different subcellular localizations of P16 to
differences in patient survival, where strong cytoplasmic
P16 was found to be prognostic for poor survival [55].
Our findings confirm findings from previous studies
reporting P53 (in BXs) as a marker for osteosarcoma pa-
tient survival prognosis [15]. However, using IHC, only
mutant P53 can be detected due to its prolonged half-life
[62-64]. Mutant P53 is often found to be incapable of in-
ducing DNA-damage signaling and thus, renders tumor
cells apoptosis resistant. An increase in mutations of P53
might be a consequence of cisplatin-based chemotherapy
[65] and proteins such as maspin might be prone to simi-
lar events and are therefore found overexpressed in osteo-
sarcoma samples. In contrast, the P16-coding CDKN2A
locus was shown to be deleted rather than mutated in
osteosarcoma samples leading to a loss of P16 expression
[66]. However, these results were derived from samples
which were chemotherapy naïve and sequencing ap-
proaches of P16 positive RXs would be required to con-
firm the absence of mutations in the CDKN2A locus.
The tumor suppressor PTEN is frequently deactivated
through deletions, leading to low or no PTEN expres-
sion in osteosarcoma samples [67]. Consequently, loss of
PTEN leads to a more malignant phenotype and a poor
patient survival. We demonstrated for the first time a
better prognosis of osteosarcoma patients if their RXs
were positively stained for PTEN. In line with our re-
sults, other studies also showed worse patient survival in
case PTEN was absent [43, 44, 68].
Patients who present with metastatic disease have gen-
erally lower survival rates than patients with localized
osteosarcomas [3]. In order to identify potential markers
of metastasis, we correlated the studied biomarkers with
the presence of metastases. Based on our results, none
of the studied biomarkers showed any correlation with
the development of metastases, irrespective of the origin
of the evaluated tissue (e.g., BXs or RXs). These results
point at a minor role of the studied biomarkers in the
process of metastasis in osteosarcoma, although markers
like P53, P16 or PTEN have a significant correlation
with the overall survival of the patients included in this
cohort study.
It is commonly known that males are more often af-
fected by osteosarcoma than females [4], yet no difference
in terms of response to chemotherapy has so far been
shown between genders. Our analysis of osteosarcoma
BXs showed a better response of female osteosarcoma-
bearing patients upon neoadjuvant chemotherapy. Al-
though the cause of this gender difference is unknown, it
is unlikely to be an artefact as this outcome is in line with
the generally higher survival rates of female osteosarcoma
patients compared to male patients [69-71].
There are some limitations to our study. First, it is lim-
ited by low sample numbers, especially with respect to
analysis of matched samples. Nevertheless, in comparison
to other studies investigating biomarkers of osteosarcoma,
our patient cohort can be considered as average sized [15].
Furthermore, additional analyses such as mutational ana-
lyses were not performed at this stage and although IHC
is a commonly used method in the clinics it does not pro-
vide complete information about the functional state of
the detected proteins. Nevertheless, IHC is a commonly
available tool to identify the expression status of a protein
in various tissues and to learn about the subcellular distri-
bution of a protein within cancer cells.
Conclusions
In conclusion, using resected material, we have identified
P16 and PTEN as prognostic markers for poor and for
good overall survival of osteosarcoma patients, respect-
ively. We also showed potential evidence of P16 in causing
poor chemotherapy response upon neoadjuvant chemo-
therapy, thus establishing a basis for future research on
the role of P16 in chemotherapy resistance. Importantly,
the use of matched BXs and RXs also allowed us to gain
more insight in the dynamics of biomarker expression fol-
lowing chemotherapy. Ultimately our study demonstrates
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that the use of RXs yields many clues regarding chemo-
therapy response and patient survival, and thus, should be
considered in addition to immunohistochemical evalu-
ation of chemotherapy naïve material.
Additional files
Additional file 1: Positive, cytoplasmic only P16 immunostaining.
This figure displays an immunostaining of P16 which is solely present in
the cytoplasm of tumor cells (arrows point at representative cancer cells).
The blue color of all nuclei is never fully covered with brown DAB
reagent, showing the extranuclear localization of the P16 staining.
Additional file 2: Kaplan- Meier survival analysis of samples
grouped according to subcellular localization of P16. P16 positive
samples were grouped according to the subcellular localization of P16,
yielding “cytoplasmic and nuclear” (cn) P16 as well as “cytoplasmic only”
(c) P16. (A) Kaplan-Meier plot showing no difference in survival rates
of BXs stratified according to c or cn subcellular localizations of P16
(P = 0.358). (B) Kaplan-Meier survival analysis using RXs yielded similar
survival rates of cn and c P16 (P = 0.845). In contrast, cnP16 and cP16
showed worse survival rates when compared to P16 negative samples
(P = 0.067 and P = 0.059, respectively). Abbreviations: BX, biopsy; c,
cytoplasmic only; cn, cytoplasmic and nuclear; RX, resection.
Additional file 3: Correlations between Ki67 IHC and IHC of other
biomarkers. In general, Ki67 is used as a marker for proliferation. To see
if the studied putatitve tumor suppressors and BMI1 can be correlated to
the proliferation state of the analyzed osteosarcoma samples, Fisher’s
exact tests were performed to evaluate significant correlations.
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